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Abstract
A 46-year-old woman under 6-year haemodialysis was ad-
mitted for uncontrollable hip pain. An X-ray film revealed
calcified mass around the ‘left femur head’, which was
diagnosed as calcium deposition by percutaneous biopsy.
Calcinotic tissues were removed surgically, and the re-
sected specimen revealed tumoral calcinosis caused by low
bone turnover. A complete resolution of calcinotic lesions
around the ‘left knee’ occurred 6 months after treatment
modification. Immunohistochemistry showed recruitment
of multi-nucleated giant cells positive for CD68, tartrate
resistantacidicphosphataseandcalcitoninreceptor,indica-
tive of osteoclast-like features. We propose the involve-
ment of osteoclast-like cells in active resorption of tumoral
calcinosis.
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Introduction
Tumoral calcinosis, an ectopic calcification occasionally
seen in haemodialysis patients, is characterized by massive
periarticular deposition of calcium (Ca) and phosphorus
(P), and various factors are involved in its pathogenesis of
tumoral calcinosis such as secondary hyperparathyroidism
and adynamic bone disease [1]. With regard to the regres-
sion of tumoral calcinosis, there have been several case
reports of haemodialysis patients who show complete res-
olution of such calcifications after appropriate treatment
[2–4]. However, the precise mechanism of such regression
remains unclear.
We present here the case of a haemodialysis patient
with tumoral calcinosis whose surgically resected spec-
imen revealed recruitment of multi-nucleated giant cells
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Fig. 1. X-ray films of tumoral calcinosis. Tumoral calcinosis around the
‘left femur head’ (A). Tumoral calcinosis around the ‘left knee’ before
changingtreatment(B).Thiscalcifiedmaterialwasnotremovedsurgically.
Note that calcification around the ‘left knee’ almost disappeared 6 months
after changing treatment (C) (arrows).
with osteoclast-like features. These cells are presumed to
play a role in the regression of tumoral calcinosis.
Case report
A 46-year-old female with 6-year history of haemodial-
ysis therapy for chronic glomerulonephritis was admitted
to Kyushu University hospital for the management of se-
vere hip pain. The past history included the appearance
C   The Author [2009].
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Fig.2. Clinicalcourse.Clinicalcoursebeforeandafterchangingtreatment.Abbreviations:i-PTH,intact-parathyroidhormone;afterchangingtreatment,
serum Ca–P product level decreased to the target range followed by regression of tumoral calcinosis around the ‘left knee’. (A) Percutaneous biopsy of
the tumoral calcinosis around the ‘left femur head’. (B) Resection of the tumoral calcinosis around the ‘left femur head’. (C) Disappearance of tumoral
calcinosis around the ‘left knee’.
Fig. 3. Immunohistochemical staining of the resected tissue of tumoral
calcinosis from around the ‘left femur head’. Immunohistochemical stain-
ing for (A) CD68, (B) tartrate-resistant acidic phosphatase (TRACP) and
(C) calcitonin receptor. Note the presence of multi-nucleated giant cells
and mononuclear cells positive for CD68, TRACP, calcitonin receptor
and (D) receptor activator of nuclear factor kappa beta (RANK) (arrows).
Magnification ×200, each.
of left hip pain about 3 years prior to admission, which
gradually worsened with time. At that stage, plain X-ray
films showed calcified masses around the ‘left femur head’
(Figure 1A) and the ‘left knee’ (Figure 1B). Six months
prior to admission, she was referred to the orthopedicians
at our hospital, and a percutaneous biopsy was performed;
histopathology revealed massive Ca deposition. Because of
the severe hip pain, the calcified mass around the ‘left fe-
murhead’wasremovedsurgically.Aftersurgery,thepatient
was transferred to our department for further management
of hypercalcaemia. At that time, tumoral calcinosis around
the ‘left knee’, which was not removed at surgery, was still
evident radiologically.
At the first consultation, 3 days after surgery, the patient
had high serum Ca level (12.2 mg/dl) (N; 8.7–10.3), high
serum P level (6.4 mg/dl) (N; 2.5–4.7), high Ca–P product
(78 mg2/dl2) and low levels of intact-parathyroid hormone
(PTH,19pg/ml)(N;10–65)andalkalinephosphatase(ALP,
109 IU/l) (N; 115–359). She had been treated for the last
6 years with alfacalcidol (0.25 μg/day), Ca bicarbonate
(1.5 g/day) and high Ca dialysate (3.0 mEq/l). Based on
thesefindings,weconcludedthatthecalcifiedmassaround
the‘leftfemurhead’and‘leftknee’wastumoralcalcinosis,
whichwascausedbylowboneturnoverfollowedbyreduced
capacity for Ca and P.
The clinical course is shown in Figure 2. We changed
the P binders to non-Ca containing ones and discontinued
alfacalcidol. We also converted the dialysate Ca concen-
tration to 2.5 mEq/l. Such changes in treatment brought in
decrease of Ca, P and Ca–P product, and then resulted in
the elevation of intact PTH and ALP and in the improve-
ment of bone turnover. Six months after switching to the
new treatment, the calcified lesions around the ‘left knee’
disappeared completely (compare Figure 1C with B). At
the last follow-up examination at the outpatient clinic, the
patient was free of pain and calcified lesions as confirmed
radiologically.
Histopathological examination of the calcified mass
around the ‘left femur head’ showed calcificationTumoral calcinosis with osteoclast-like cells 157
areas surrounded by many multi-nucleated giant cells
and mononuclear cells with fibrous tissues. Immunohis-
tochemical staining showed that the multi-nucleated cells
and mononuclear cells were positive for CD68, TRACP
(tartrate-resistant acidic phosphatase, calcitonin receptor)
and RANK (receptor activator of nuclear kappa beta)
(Figure 3A–D).
Discussion
Wepresentherethecaseofahaemodialysis patientwithtu-
moral calcinosis caused by low bone turnover. Tumoral cal-
cinosisinonesitewassurgicallyresectedandtumoralcalci-
nosisinanothersiteregressedspontaneouslyaftertreatment
modification. The surgically resected specimen revealed
recruitment of multi-nucleated giant cells positive for
CD68 and calcitonin receptor, indicative of osteoclast-like
features.
Previous histopathological studies of resected tissues
of tumoral calcinosis have already reported the presence
of multi-nucleated giant cells and inflammatory cells sur-
rounding the calcified region [5], and several groups have
providedsomeexplanationfortheregressionofectopiccal-
cification [6–8]. Veress et al. [7] histopathologically evalu-
ated 20 patients with tumoral calcinosis, and proposed the
involvement of the multi-nucleated giant cells in the re-
gression process. Using a rat model, Bas et al. [8] found
infiltrating CD68-positive mononuclear cells in the walls
of calcified artery and reported the reversibility of arterial
medial calcification. Although these two reports indicated
the association of CD68-positive cells with regression of
ectopic calcifications, they did not fully describe all the
features of the giant cells.
In our patient, the multi-nucleated giant cells and
mononuclear cells around the calcified masses were pos-
itive for CD68, TRACP and calcitonin receptor. Thus,
these multi-nucleated giant cells are phenotypically sim-
ilar to osteoclasts since CD68 is a marker of macrophage
differentiation and TRACP and calcitonin receptor are
markers of osteoclasts. We also found these giant cells
positive for RANK, which is essential for osteoclast matu-
ration in the bone into activated osteoclasts that can inter-
act with RANK-ligand [9]. Thus, we hypothesized that the
mononuclear cells of macrophage lineage are recruited to
tumoral calcinosis and eventually become multi-nucleated
giant cells with osteoclast-like phenotype by fusion, where
they participate in resorption of the calcified material sim-
ilar to the resorption of bone by osteoclasts.
Regarding the regression process in tumoral calcinosis,
we speculate that such process depends on the relative
balance between passive accumulation and active resorp-
tion of Ca–P products. It is likely that the osteoclast-like
multi-nucleated giant cells are involved in removal of cal-
cified material during the active resorption process. This
hypothesis is proven by the clinical results that appropri-
ate medical and surgical treatment can occasionally lead to
spontaneous regression of tumoral calcinosis [2–4]. In the
present case, before changing treatment, passive accumu-
lation was dominant over active resorption. After changing
treatment, the bone turnover improved, and active resorp-
tionprocessbecamerelativelydominant.Finally,regression
of tumoral calcinosis around the ‘left knee’ was evident
radiologically.
The present report has a few limitations. First, the speci-
men examined was from the ‘left femur head’ and not from
the ‘left knee’ where spontaneous regression was noted.
Second, whereas recruitment of giant cells was demon-
strated, no evidence of activation and phagocytosis by giant
cells was presented.
In summary, we described here the case of a haemodial-
ysis patient with tumoral calcinosis whose surgically re-
sected specimen revealed recruitment of multi-nucleated
giant cells with osteoclast-like features. We conclude that
these cells were involved in the active resorption process of
tumoral calcinosis.
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